Related Experiment Video
Updated: Apr 19, 2026
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Trabectedin for advanced soft tissue sarcomas: optimizing use
Alison Reid1, Juan Martin-Liberal1, Charlotte Benson1
1Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Abstract:
Patients with locally advanced or metastatic soft tissue sarcoma have a poor outlook with median survival in the order of 1 year. There is therefore an urgent need for novel agents to impact this disease. Trabectedin is one such novel agent that has demonstrated activity for patients with advanced soft tissue sarcoma and it was licensed in Europe in 2007 for patients in the second-line setting or first-line in those patients deemed unsuitable to receive cytotoxics. In order to best serve patients with novel agents, it is imperative to understand the mechanism or mechanisms of action and the best ways of assessing response in order to optimize antitumor activity. Frequently, the mechanism of action and the optimal means of assessing response will be different from those of traditional cytotoxics. Trial design should reflect these factors to ensure that active drugs are not wrongly marked as futile. This review discusses a number of factors that may influence the optimization of trabectedin use. These factors include the administration schedule, the optimal timing of trabectedin administration in the disease process, the histopathological and molecular subtypes that may be most sensitive to trabectedin, the challenge of assessing response, particularly using radiology, and, finally, the safety considerations with this agent.
Insights
Novel agent trabectedin shows promise for advanced soft tissue sarcoma. Optimizing its use requires understanding mechanisms, administration, and response assessment for better patient outcomes.
Area of Science:
- Oncology
- Pharmacology
Background:
- Soft tissue sarcoma (STS) is a rare cancer with poor prognosis in advanced stages.
- Current treatments have limitations, necessitating novel therapeutic agents.
- Trabectedin is an approved agent for advanced STS, but its optimal use requires further investigation.
Purpose of the Study:
- To review factors influencing the optimization of trabectedin use in soft tissue sarcoma.
- To discuss the mechanism of action and response assessment for trabectedin.
- To highlight considerations for trial design and clinical application of trabectedin.
Main Methods:
- Literature review of trabectedin's efficacy and mechanism in soft tissue sarcoma.
- Analysis of factors affecting trabectedin's antitumor activity.
- Discussion of challenges in assessing treatment response, particularly radiologically.
Main Results:
- Trabectedin demonstrates activity in advanced STS, particularly in second-line or alternative first-line settings.
- Understanding trabectedin's unique mechanism of action is crucial for optimizing its use.
- Administration schedule, timing, patient selection, and response assessment are key factors.
Conclusions:
- Optimizing trabectedin administration, timing, and patient selection can enhance its antitumor activity.
- Accurate response assessment, distinct from traditional cytotoxic agents, is vital.
- Further research into trabectedin's specific applications and safety profile is warranted for improved STS management.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules